ArticlePloS one2025
Effect of intranasal administration of Erigeron annuus and Carthamus tinctorius extracts in a rat model of olfactory dysfunction induced by 3-methylindole.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global research trends and hotspot evolution of olfactory dysfunction from 2014 to 2024: a bibliometric analysis.Annals of medicine and surgery (2012) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are many factors that can cause olfactory dysfunction, including upper respiratory tract viral infections, non-inflammatory respiratory diseases, trauma, and current treatments such as medications and surgery can have adverse effects and may not respond. Therefore, we aimed to develop a natural product-based adjunctive treatment strategy for olfactory dysfunction that is safe and has minimal adverse effects. We investigated the effects of extracts from Erigeron annuus and Carthamus tinctorius, which have demonstrated anti-apoptotic, neuroprotective, and anti-inflammatory activities, on 3-methylindole-induced olfactory dysfunction. A 3-methylindole-induced olfactory dysfunction model rat was established and olfactory dysfunction was treated with intranasal administration of Erigeron annus extract (EAE) and Carthamus tinctorius extract (CTE) or their combination. After 3 weeks, alterations in food-finding tests and OMP expression in olfactory bulb and olfactory epithelium were assessed. Comparing the food finding test, the EAE + CTE group had a significant decrease in food finding time compared to the vehicle group. IHC and Western blot analyses showed that OMP expression in the olfactory bulb was significantly increased in the EAE + CTE group compared to the vehicle group. Western blot analysis of olfactory epithelial tissue also showed a significant increase in OMP expression. Intranasal administration of EAE + CTE alleviated 3-methylindole-induced olfactory dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.